Menu

Opioid Safety Strategies: Reducing Harm to Our Patients, Colleagues, and Community

  • Claim Credits by 8/29/2024
  • Online Activity
Credits Available: CME, Patient Safety, Quality Improvement (Part 4)

This activity is supported in part by a medical education grant from Masimo and an unrestricted educational grant from Medtronic.

This program consists of 2 modules: Module 1 is the didactic component and offers 2 patient safety credits; Module 2 is...  Read More +




Item Details

The American Society of Anesthesiologists is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The American Society of Anesthesiologists designates this enduring material activity for a maximum of 6 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Maintenance of Certification in Anesthesiology® and MOCA® are registered certification marks of The American Board of Anesthesiology®. MOCA 2.0® is a trademark of the American Board of Anesthesiology®.

This activity offers up to 6 CME credits (2 patient safety credits for completion of module 1; 4 CME credits, and 4 MOCA part 4 QI points for completion of module 2), of which 2 credits contribute to the patient safety CME component of the American Board of Anesthesiology’s redesigned Maintenance of Certification in Anesthesiology® (MOCA®) program, known as MOCA 2.0®. Please consult the ABA website, www.theABA.org, for a list of all MOCA 2.0 requirements.

Access the course.

At the conclusion of this activity, participants will be able to: 

Part I: Background on Opioids

  • Summarize common limitations associated with the antagonism of opioids. 

Part II: Hospital Inpatient Opioid Overdose

  • Define the clinical populations at risk of opioid overdose. 
  • Describe the appropriate criteria and dosing regimen for naloxone in the treatment of opioid overdose.
  • Compare methods of non-invasive respiratory monitoring to assess for opioid-induced respiratory depression (OIRD).

Part III: Community Opioid Overdose

  • Define the community populations at risk of opioid overdose.
  • Explain the importance of bystander rescue for victims of opioid overdose.
  • List the formulations of naloxone available to the lay public to rescue victims of opioid overdose.
  • Differentiate between opioid antagonism in the community setting vs. the healthcare setting.

Part IV: The Impaired Practitioner

  • Describe the scope of substance use disorder in healthcare professionals.
  • Review the process for approaching the healthcare professional who is suspected of substance use disorder.
All members of the anesthesia care team as well as pharmacists, surgeons and hospitalists
Jonathan Cohen, MD, MS, CPPS, FASA; Meera Gangadharan, MD, FAAP, FASA; Michael G. Fitzsimons, MD; David S. Craig, PharmD

Disclosure Statement: The American Society of Anesthesiologists remains strongly committed to providing the best available evidence-based clinical information to participants of this educational activity and requires an open disclosure of any potential conflict of interest identified by our faculty members. It is not the intent of the American Society of Anesthesiologists to eliminate all situations of potential conflict of interest, but rather to enable those who are working with the American Society of Anesthesiologists to recognize situations that may be subject to question by others. All disclosed conflicts of interest are reviewed by the educational activity course director/chair to ensure that such situations are properly evaluated and, if necessary, resolved. The American Society of Anesthesiologists educational standards pertaining to conflict of interest are intended to maintain the professional autonomy of the clinical experts inherent in promoting a balanced presentation of science. Through our review process, all American Society of Anesthesiologists activities are ensured of independent, objective, scientifically balanced presentations of information. Disclosure of any or no relationships will be made available for all educational activities.

Disclosures: The following faculty and planning committee members have indicated that they have relationships with ineligible companies to disclose:

David Craig, PharmD
Meter Health – Consultant
Trevena – Consultant

Jeffrey Green, MD, MSHA, FASA
Cerus Corporation – Grant / Contract
La Jolla Pharmaceutical Company – Consultant
Medtronic – Consultant

Senthilkumar Sadhasivam, MD, MPH, MBA, FASA
NeurOptics – Consultant

The above financial relationships have been mitigated.

All other planners, faculty, and staff have reported no relevant financial relationships with ineligible companies to disclose.

Adobe Acrobat Reader, Internet connection, Media Player. Web browser version must have been released within the last three years.
Opioid Safety Strategies: Reducing Harm to Our Patients, Colleagues, and Community
  • Non-member Price: $83.00
  • Member Price: $52.00
Log in to receive your price
 
Want to save more?
Log into see if you qualify for a lower rate.
Members save $31.00 or more Join